Methylergonovine (Methergine) is an ergot alkaloid used for prevention and treatment of postpartum hemorrhage due to uterine atony. It is a second-line agent after oxytocin. Postpartum hemorrhage (PPH): - Defined as cumulative blood loss ≥1000 mL OR blood loss accompanied by signs/symptoms of hypovolemia within 24 hours after delivery - Most common cause: uterine atony (failure of uterus to contract after placental delivery) — accounts for 70–80% of PPH When methylergonovine is used: 1. When oxytocin alone is insufficient to control PPH 2. When uterine atony persists after initial oxytocin 3. As part of a multi-agent PPH treatment protocol On the exam, writers often pair stable-sounding options with unstable data—notice the mismatch before you commit. If the stem names a license or role, reread that line; scope errors are classic trap answers even when the clinical topic is familiar. Run a 60-second scan: breathing work and oxygenation, perfusion and end organs, neuro baseline, likely infection sources, and devices that can fail quietly. When two answers feel partly right, pick the one that reduces imminent harm and matches orders for the...